National Heart, Lung, and Blood Institute and American Association for Thoracic Surgery Workshop Report: Identifying collaborative clinical research priorities in lung transplantation

Abstract

In 2016, more than 2300 lung transplants were performed in the United States, and approximately 2700 candidates were added to the wait-list. 1 Clinical outcomes after lung transplantation lag behind those achieved with transplantation of other solid organs, with average 5-year survival of 55%. 1 Despite this, lung transplantation is a relatively understudied area of clinical research, and few prospective randomized trials are conducted in lung transplantation. In June 2017, the National Heart, Lung, and Blood Institute (NHLBI) and American Association for Thoracic Surgery (AATS) co-sponsored a workshop designed to bring participants together to summarize the current state of the science in adult lung transplantation, identify knowledge gaps, and determine priorities in clinical lung transplant research that could be addressed in the near future. Workshop topics were initially drafted by the AATS with input from the International Society for Heart and Lung Transplantation (ISHLT), and then finalized by the NHLBI and AATS leadership. Workshop participants included leaders in lung transplantation with specific expertise in thoracic surgery, pulmonary medicine, and bioethics. Although all present acknowledged that chronic lung allograft From the

Factors affecting complications development and mortality after single lung transplant

“…A prospective study by Diamond et al [ 18 ] between 2002 and 2010 registered PGD3-30.8% in the first 72 h after LT. Furthermore, Mulligan et al [ 1 ] reported that PGD3 correlated with a mortality rate of 23% in 3 post-operative months and 34% in 1 year, compared to 5% and 11% for those without PGD, respectively.…”

“…Lung transplantation (LT) is a life-saving therapeutic procedure that prolongs survival in patients with end-stage lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and alpha-1 antitrypsin deficiency[ 1 ]. Since the first successful LT in 1981, there have been many improvements in surgical and anesthetic procedures[ 2 ].…”